MedPath
FDA Approval

Eptifibatide

FDA-approved pharmaceutical product with comprehensive regulatory information, manufacturing details, and complete labeling documentation.

FDA Approval Summary

Company
Effective Date
May 28, 2021
Labeling Type
HUMAN PRESCRIPTION DRUG LABEL
Eptifibatide(0.75 mg in 1 mL)

Products3

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Eptifibatide

Product Details

NDC Product Code
67457-631
Application Number
ANDA203258
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
December 17, 2018
Code: NA8320J834Class: ACTIBQuantity: 0.75 mg in 1 mL
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QPClass: IACTQuantity: 5.25 mg in 1 mL
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT

Eptifibatide

Product Details

NDC Product Code
67457-629
Application Number
ANDA203258
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
December 17, 2018
Code: NA8320J834Class: ACTIBQuantity: 2 mg in 1 mL
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QPClass: IACTQuantity: 5.25 mg in 1 mL
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT

Eptifibatide

Product Details

NDC Product Code
67457-630
Application Number
ANDA203258
Marketing Category
ANDA (C73584)
Route of Administration
INTRAVENOUS
Effective Date
December 17, 2018
CITRIC ACID MONOHYDRATEInactive
Code: 2968PHW8QPClass: IACTQuantity: 5.25 mg in 1 mL
SODIUM HYDROXIDEInactive
Code: 55X04QC32IClass: IACT
Code: NA8320J834Class: ACTIBQuantity: 2 mg in 1 mL
© Copyright 2025. All Rights Reserved by MedPath